Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis

Cancer Research

Volumn 59, Issue 2, 1999, Pages 347-352

  Viti, Francesca ^a   Tarli, Lorenzo ^a   Giovannoni, Leonardo ^b   Zardi, Luciano ^c   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF SIENA   (Italy)

^c CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FIBRONECTIN; RECOMBINANT ANTIBODY;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TARGET ORGAN; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; FIBRONECTINS; IMMUNOGLOBULIN FRAGMENTS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; TERATOCARCINOMA; TISSUE DISTRIBUTION;

EID: 0033555628     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
2. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
3. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell, 88: 277-285, 1997.
4. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresh, D. A. Definition of two angiogenic pathways by distinct α-v integrins. Science (Washington DC), 270: 1500-1502, 1995.
5. Pasqualini, R., Koivunen, E., and Ruoslahti, E. α-v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 15: 542-546, 1997.
6. Huang, H., Molema, G., King, S., Watkims, L., Edgington, T. S., and Thorpe, P. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor neo-vasculature. Science (Washington DC), 275: 547-550, 1997.
7. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
8. Schmidt-Erfurth, U., Diddens, H., Birngruber, R., and Hasan, T. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br. J. Cancer, 75: 54-61, 1997.
9. Clauss, M. A., and Jain, R. K. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res., 50: 3487-3492, 1990.
10. Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., and Weiner, L. M. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res., 58: 485-490, 1998.
11. King, D. J., Turner, A., Farnsworth, A. P. H., Adair, J. R., Owens, R. J., Pedley, R. B., Baldock, D., Proudfoot, K. A., Lawson, A. D. G., Beeley, N. R. A., Millar, K., Millican, T. A., Boyce, B. A., Antoniw, P., Mountain, A., Begent, R. H. J., Schocat, D., and Yarranton, G. T. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res., 54: 6176-6185, 1994.
12. Neri, D., Carnemolla, B., Nissim, A., Balza, E., Leprini, A., Querzè, G., Pini, A., Tarli, L., Halin, C., Neri, P., Zardi, L., and Winter, G. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat, Biotechnol., 15: 1271-1275, 1997.
13. Zardi, L. Carnemolla, B., Siri, A., Petersen, T. E., Paolella, G., Sebastio, G., and Baralle, F. E. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J., 6: 2337-2342, 1987.
14. Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., and Natali, P. G. A tumor-associated fibronectin isoform generated by alternative splicing of messanger RNA precursors. J. Cell Biol., 108: 1139-1148, 1989.
15. Castellani, P., Viale, G., Dorcaratto, A., Nicolò, G., Kaczmarek, J., Querzè, G., and Zardi, L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer, 59: 612-618, 1994.
16. Kaczmarek, J., Castellani, P., Nicolò, G., Spina, B., Alemanni, G., and Zardi, L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer, 58: 11-16, 1994.
17. Carnemolla, B., Neri, D., Castellani, P., Leprini, A., Neri, G., Pini, A., Winter, G., and Zardi, L. High-affinity human recombinant antibodies to the oncofetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer, 68: 397-405, 1996.
18. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., and Neri, D. Design and use of a phage-display library: human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem., 273: 21769-21776, 1998.
19. 32P]-ATP. Nat. Biotechnol., 14: 385-390, 1996.
20. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning, A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1990.
21. Munro, S., and Pelham, H. R. B. An Hsp-like protein in the ER: identity with the 78 kD glucose regulated protein and immunoglobulin heavy chain binding protein. Cell, 46: 291-300, 1986.
22. Jönsson, U., Fägerstam, L., Ivarsson, B., Johnsson, B., Karlsson, R., Lundh, K., Löfås, S., Persson, B., Roos, H., Rönnberg, I., Sjölander, S., Stenberg, E., Ståhlberg, Urbaniczky, C., Östlin, H., and Malmqvist, M. Real-time bispecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques. 11: 620-627, 1991.
23. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol., 12: 433-455, 1994.
24. Figini, M., Marks, J. D., Winter, G., and Griffiths, A. D. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J. Mol. Biol., 239: 68-78, 1994.
25. Jespers, L. S., Roberts, A., Mahler, S. M., Winter, G. and Hoogenboom, H. R. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Bio/Technology, 12: 899-903, 1994.
26. Low, N., Holliger, P., and Winter, G. Mimicking somatic hypermutations: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol., 260: 359-368, 1996.
27. Yang, W., Green, K., Pinz-Sweeney, S., Briones, A. T., Burton, D. R., and Barbas, C. F., III. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-21 antibody into the picomolar range. J. Mol. Biol., 254: 392-403, 1995.
28. Schier, R., Balint, R. F., McCall, A., Apell, G., Larrick, J. W., and Marks, J. D. Identification of functional and structural amino acid residues by parsimonious mutagenesis. Gene (Amst.), 169: 147-155, 1996.
29. Huston, J. S., Levinson, D., Mudgett, H. M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J. Bruccoleri, R. E., Haber, E., Crea, R., Oppermann, H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA, 85: 5879-5883, 1988.
30. Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S., and Whitlow, M. Single-chain antigen-binding proteins. Science (Washington DC), 242: 423-426, 1988.
31. Holliger, P., Prospero, T., and Winter, G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA, 90: 6444-6448, 1993.
32. Neri, D., Montigiani, S., and Kirkham, P. M. Biophysical methods for the determination of antibody-antigen affinities. Trends Biotechnol., 14: 465-470, 1996.
33. Crothers, D. M., and Metzger, H. The influence of polyvalency on the binding properties of antibodies. Immunochemistry, 9: 341-357, 1972.
34. Adams, G. P., McCartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L., and Weiner, L. M. Highlly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single chain Fv. Cancer Res., 53: 4026-4034, 1993.
35. Salacinski, P. R. P., McLean, C., Sykes, J. E. C., Clement-Jones, V. V., and Lowry, P. J. Iodination of proteins, glycoproteins and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3α,6 α -diphenyl glycoluril (Iodogen). Anal. Biochem., 117: 136-146, 1981.
36. Wu, A. M., Chen, W., Raubitschek, A., Williams, L. E., Neumaier, M., Fischer, R., Hu, S., Odom-Maryon, T., Wong, J. Y. C., and Shively, J. E. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology (Shannon), 2: 21-36, 1996.
37. 2 and Fab fragments and recombinant scFv in a human tumour xenograft model. Tumor Targeting, 2: 37-48, 1996.
38. Carter, P., Kelley, R. F., Rodrigues, M., Snedecor, B., Covarrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts, C. E., Carver, M. E., Yang, M., Bourell, J. H., Shephard, H. M., and Henner, D. High level Echerichia coli expression anp production of a bivalent humanized antibody fragment. Bio/Technology, 10: 163-167, 1992.
39. Pack, P., Kujau, M., Schroeckh, V., Knüpfer, U., Wenderoth, R., Riesenberg, D., and Plückthun, A. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Bio/ Technology, 11: 1271-1277, 1993.
40. Ridder, R., Schmitz, R., Legay, F., and Gram, H. Generation of rabbit monoclonal antibody fragments from a combinatorial phage display lybrary and their production in the yeast Pichia Pastoris. Bio/Technology, 13: 255-260, 1995.
41. Casey, J. L., Keep, K. A., Chester, L., Robson, L., Hawkins, R. E., and Begent, R. H. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J. Immunol. Methods. 179: 105-116, 1995.
42. Colcher, D., Minelli, F. M., Roselli, M., Muraro, R., Simpson-Milenic, D., and Schlom, J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res., 48: 4597-4603, 1988.
43. Kosmas, C., Linardou, H., and Epenetos, A. A. Advances in monoclonal antibody tumour targeting. J. Drug Target., 1: 81-91, 1993.
44. Begent, R. H. J., Verhaar, M. J., Chester, K. A., Green, A. J., Napier, M. P., Hope-Stone, L. D., Cushen, N., Keep, P. A., Johnson, C. J., Hawkins, R. E., Hilson, A. J. W. and Robson, L. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med., 2: 979-984, 1996.
45. Folli, S., Westermann, P., Braichotte, D., Pelegrin, A., Weignieres, G., van der Bergh, H., and Mach, J. P. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res., 54: 2643-2649, 1994.
46. Neri, D., and Zardi, L. Affinity reagents against tumor-associated extracellular molecules and new-forming vessels. Adv. Drug Delivery Rev., 31: 43-52, 1998.
47. Brekken, R. A., Huang, X., King, S. W., and Thorpe, P. E. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res., 58: 1952-1958, 1998.